PURE Bioscience, Inc. reported fiscal first‑quarter 2026 results for the period ended October 31, 2025, showing net product sales of $707,000, a 27% increase from $555,000 in the same quarter a year earlier. The company’s net loss narrowed to $464,000 from $689,000 in the prior year, reflecting stronger revenue and improved cost control.
Gross margin rose to 64% from 58% year‑over‑year, driven by a higher mix of higher‑value packaging and a shift toward more profitable product lines. Operating expenses fell to $829,000, down 12% from $952,000 a year earlier, largely due to a $722,000 reduction in selling, general and administrative costs, including headcount and marketing spend.
Sales growth was led by the produce industry, where the PURE Control® product was adopted for leafy‑green treatment, and by the transportation segment, which also saw increased demand. President Jeff Kitchell noted that “our fiscal first‑quarter year‑over‑year sales growth shows the progress we have made with our direct customers and distribution network. We are continuing to grow our core produce business.”
Despite the revenue gains, the company remains in a net‑loss position and faces significant financial headwinds. An auditor’s “going concern” note highlights doubts about the company’s ability to continue operations, citing recurring losses, negative operating cash flow, and a stockholders’ deficiency. Cash and restricted cash totaled $509,000, up from $421,000 at the end of the prior quarter, supported by $350,000 in new convertible note proceeds.
Management emphasized continued focus on cost discipline and expanding product adoption, while acknowledging the need for additional financing to sustain growth. The company’s financial structure, heavily reliant on convertible notes, underscores the importance of maintaining liquidity as it works toward profitability.
The results underscore a mixed outlook: revenue growth and margin improvement signal progress, but ongoing losses and liquidity concerns suggest that the company’s path to profitability remains uncertain.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.